×
About 1,950 results
Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2733171
JAMA Network Open; Hsiang, E. et. al.

May 9th, 2019 - Question Are breast and colorectal cancer screening rates associated with the time of day a patient visits the primary care clinician? Findings In this quality improvement study analysis of 33 primary care practices including 19 254 patients eligible for breast cancer screening and 33 468 patients eligible for colorectal cancer screening, both clinician ordering and patient completion of c...

FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need
https://www.cytodyn.com/media/press-releases/detail/328/fda-grants-cytodyn-fast-track-designation-for-leronlimab

May 6th, 2019 - CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to leronlimab (PRO140) for use in combination with carboplatin for the treatment of patients...

FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
https://www.gene.com/media/press-releases/14785/2019-05-03/fda-approves-genentechs-kadcyla-for-adju

May 2nd, 2019 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla® (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women with ovarian cancer. The recommendations focus on pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurre...

Antioxidant; Camellia sinensis; Free radical; Green tea; Matcha
http://www.cqaimh.org/pdf/tool_phq9.pdf

Apr 18th, 2019 - The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Screening for Elevated Blood Lead Levels in Children and Pregnant Women: US Preventive ... Preview
https://doi.org/10.1001/jama.2019.3326
JAMA , Curry SJ et. al.

Apr 16th, 2019 - Elevated blood lead levels in children are associated with neurologic effects such as behavioral and learning problems, lower IQ, hyperactivity, hearing problems, and impaired growth. In pregnant women, lead exposure can impair organ systems such as the hematopoietic, hepatic, renal, and nervous systems, and increase the risk of preeclampsia and adverse perinatal outcomes. Many of the adverse h...

Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians
https://annals.org/aim/fullarticle/2730520/screening-breast-cancer-average-risk-women-guidance-statement-from-american

Apr 8th, 2019 - Description: The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include. Methods: This guidance statement is derived from an appraisal of selected guidelines from around the world that address breast cancer screening, as well as their included evidence. All...

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
https://wwwext.amgen.com/media/news-releases/2019/04/fda-approves-evenity-romosozumabaqqg-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture/

Apr 8th, 2019 - Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (...

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer

Apr 3rd, 2019 - Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Th...

Direct-to-consumer genetic testing
https://www.ama-assn.org/delivering-care/precision-medicine/direct-consumer-genetic-testing

Apr 2nd, 2019 - Types of DTC genetic tests A broad range of genetic test types are offered DTC, including: Carrier testing for diseases such as cystic fibrosis and hemochromatosis Pharmacogenomic testing Testing for predisposition to complex diseases such as hereditary cancers, cardiovascular disease and depression Whole exome or genome sequencing Testing to determine ancestry

The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy
https://www.abstractsonline.com/pp8/
Mudgway, R. et. al.

Apr 2nd, 2019 - Objective: While prior studies evaluating the survival benefit from primary site surgery in stage IV breast cancer patients have provided mixed results, it has been well documented that anti-human epidermal growth factor receptor (HER) therapy for metastatic HER2 positive(+) disease improves outcomes. We sought to examine the impact of primary tumor resection on survival in HER2+ stage IV breas...

Surgery associated with increased survival for patients with HER2+ stage 4 breast cancer
https://www.eurekalert.org/pub_releases/2019-04/aafc-saw032519.php

Apr 1st, 2019 - Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. Between 20 and 30 percent of all newly diagnosed stage 4 breast cancer cases are HER2+, explained the study's lead author, Ross Mudgway, a medical stud...

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30029-4/fulltext
The Lancet Oncology; Moore, K. et. al.

Mar 31st, 2019 - Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5–9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.

Center for Male Contraceptive Research & Development
https://www.malecontraception.center/

Mar 25th, 2019 - The Center for Male Contraceptive Research & Development is your official source for information and regular updates on Male Hormonal Contraception

Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Opportunistic-Salpingectomy-as-a-Strategy-for-Epithelial-Ovarian-Cancer-Prevention

Mar 25th, 2019 - Opportunistic salpingectomy may offer obstetrician–gynecologists and other health care providers the opportunity to decrease the risk of ovarian cancer in their patients who are already undergoing pelvic surgery for benign disease. By performing salpingectomy when patients undergo an operation during which the fallopian tubes could be removed in addition to the primary surgical procedure (eg, h.

The Use of Antimüllerian Hormone in Women Not Seeking Fertility Care
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Use-of-Antimullerian-Hormone-in-Women-Not-Seeking-Fertility-Care

Mar 25th, 2019 - Antimüllerian hormone is produced by the granulosa cells surrounding each oocyte in the developing ovarian follicle. The production and serum levels of antimüllerian hormone at any given time are reflective of a woman’s ovarian reserve, and multiple studies have demonstrated that antimüllerian hormone levels decline across the reproductive lifespan.

Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients, According to Researchers from Duke University
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1452

Mar 18th, 2019 - New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score (RS) testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy. The RS test helps...

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-fda-approval-zulressotm-brexanolone

Mar 18th, 2019 - Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced today the U.S. Food and Drug Administration (FDA) has approved ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most co...

AAP Updates Vaccine Recommendations for 2019-2020 Flu Season
https://www.aap.org/en-us/about-the-aap/aap-press-room/Pages/AAP-Updates-Vaccine-Recommendations-for-2019-2020-Flu-Season.aspx

Mar 13th, 2019 - The American Academy of Pediatrics (AAP) will advise families to vaccinate their children against influenza next season with either the flu shot or the nasal spray vaccine for the best protection against the virus during the 2019-2020 flu season. The recommendation differs slightly from last year, when AAP cited a preference for the injected vaccine over the nasal spray - except in cases whe...